Short Interest in Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) Drops By 83.3%

Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) was the recipient of a large decline in short interest in the month of February. As of February 28th, there was short interest totalling 349,800 shares, a decline of 83.3% from the February 13th total of 2,100,000 shares. Approximately 3.5% of the company’s shares are short sold. Based on an average daily trading volume, of 6,960,000 shares, the days-to-cover ratio is presently 0.1 days.

Petros Pharmaceuticals Trading Down 12.3 %

Shares of NASDAQ PTPI traded down $0.01 during trading on Wednesday, reaching $0.09. The company had a trading volume of 7,687,321 shares, compared to its average volume of 2,101,118. Petros Pharmaceuticals has a 12 month low of $0.07 and a 12 month high of $1.67. The company has a quick ratio of 0.74, a current ratio of 0.85 and a debt-to-equity ratio of 1.58. The stock has a market cap of $1.02 million, a P/E ratio of -0.02 and a beta of 2.04. The company’s fifty day moving average price is $0.25 and its 200-day moving average price is $0.30.

About Petros Pharmaceuticals

Petros Pharmaceuticals, Inc, a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).